MK254
JF-Expert Member
- May 11, 2013
- 31,757
- 48,404
Kwa wale hutamani kuzamia USA hii fursa ya wazi, chanjo iko tayari na USA wametangaza wakiomba mjitokeze mlio tayari kufanyiwa majaribio ya uwezo wake kuzuia kirusi cha Corona.
Wanahitaji watu 45, majasiri wa kuokoa dunia mnakaribishwa mkajitoe mhanga, mkifaulu utalipwa vizuri na unaweza ukabaki huko huko unakula bata, ila kirusi kikiipiga chanjo basi ndio hivyo tunakufukia ardhini.
====
Researchers in Seattle have begun recruiting healthy volunteers to participate in a clinical trial for an experimental COVID-19 vaccine, according to news reports.
The vaccine, developed by the biotechnology company Moderna Therapeutics, was initially sent to the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland on Feb. 24, according to The Wall Street Journal.
The agency anticipates launching a clinical trial by the end of April and will sponsor the Kaiser Permanente Washington Health Research Institute to conduct the testing, NIAID Director Anthony Fauci told The Wall Street Journal.
Forty-five healthy volunteers between the ages of 18 and 55 will be enrolled in the initial trial, which aims to determine whether the vaccine triggers an immune response, and whether the given dose causes adverse side effects, according to a description on ClinicalTrials.gov.
Source: Live Science
Wanahitaji watu 45, majasiri wa kuokoa dunia mnakaribishwa mkajitoe mhanga, mkifaulu utalipwa vizuri na unaweza ukabaki huko huko unakula bata, ila kirusi kikiipiga chanjo basi ndio hivyo tunakufukia ardhini.
====
Researchers in Seattle have begun recruiting healthy volunteers to participate in a clinical trial for an experimental COVID-19 vaccine, according to news reports.
The vaccine, developed by the biotechnology company Moderna Therapeutics, was initially sent to the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland on Feb. 24, according to The Wall Street Journal.
The agency anticipates launching a clinical trial by the end of April and will sponsor the Kaiser Permanente Washington Health Research Institute to conduct the testing, NIAID Director Anthony Fauci told The Wall Street Journal.
Forty-five healthy volunteers between the ages of 18 and 55 will be enrolled in the initial trial, which aims to determine whether the vaccine triggers an immune response, and whether the given dose causes adverse side effects, according to a description on ClinicalTrials.gov.
Source: Live Science